Study register · detail
Clear benefit
GRADE
Moderate
873 citations
Samplen = 50.087 Pat.
DurationFollow-up 1969–70 until study…
ControlNo cannabis use
EndpointHospital admission due to…
Blindingn.a.
DesignHistorische Kohortenstudie
Key finding
Dose-dependent increased risk of schizophrenia with cannabis use, not explainable by other drugs or personality traits.
Summary
n=50.087 Swedish conscripts (1969 cohort), long-term follow-up for schizophrenia hospitalisation. Dose-dependent increase in risk: adjusted OR for >50 times use 6,7 (95% CI 2,1–21,7) in the cannabis-only group; OR trend for increasing use 1,2 (95% CI 1,1–1,4, p<0,001). Association robust after controlling for other drugs and personality traits.
P
PopulationSwedish conscripts of the 1969 birth cohort (>97% of the male population aged 18–20 years), n=50.087
I
InterventionSelf-reported cannabis use (frequency-dependent, incl. subgroup exclusively using cannabis without other drugs)
C
ControlNo cannabis use (reference group within the cohort)
O
OutcomeAdjusted OR for linear trend of increasing cannabis frequency: 1,2 (95% CI 1,1–1,4, p<0,001); for exclusive cannabis use OR 1,3 (1,1–1,5, p=0,015); >50 times use (cannabis-only): OR 6,7 (2,1–21,7)
Confidence in the evidence
Moderate
The third of four GRADE levels, the effect estimate is probably reliable.
Quality profile
Sample size
★★★★★
Blinding
—
Effect size
Clear benefit
Citations / year
★★★★★
Authors
Share
Abstract
<h4>Objectives</h4>An association between use of cannabis in adolescence and subsequent risk of schizophrenia was previously reported in a follow up of Swedish conscripts. Arguments were raised that this association may be due to use of drugs other than cannabis and that personality traits may have confounded results. We performed a further analysis of this cohort to address these uncertainties while extending the follow up period to identify additional cases.<h4>Design</h4>Historical cohort study.<h4>Setting</h4>1969-70 survey of Swedish conscripts (>97% of the country's male population aged 18-20).<h4>Participants</h4>50 087 subjects: data were available on self reported use of cannabis and other drugs, and on several social and psychological characteristics.<h4>Main outcome measures</h4>Admissions to hospital for ICD-8/9 schizophrenia and other psychoses, as determined by record linkage.<h4>Results</h4>Cannabis was associated with an increased risk of developing schizophrenia in a dose dependent fashion both for subjects who had ever used cannabis (adjusted odds ratio for linear trend of increasing frequency 1.2, 95% confidence interval 1.1 to 1.4, P<0.001), and for subjects who had used only cannabis and no other drugs (adjusted odds ratio for linear trend 1.3, 1.1 to 1.5, P<0.015). The adjusted odds ratio for using cannabis >50 times was 6.7 (2.1 to 21.7) in the cannabis only group. Similar results were obtained when analysis was restricted to subjects developing schizophrenia after five years after conscription, to exclude prodromal cases.<h4>Conclusions</h4>Cannabis use is associated with an increased risk of developing schizophrenia, consistent with a causal relation. This association is not explained by use of other psychoactive drugs or personality traits relating to social integration.
The impediment to action advances action.